Rheumatoid Arthritis

Rheumatoid arthritis in dogs is an immune-mediated inflammatory joint disease characterized by progressive destruction of synovial joints due to an inappropriate immune response targeting the body's own joint tissues. Unlike osteoarthritis, which results from mechanical wear and degenerative changes, rheumatoid arthritis involves active immune-mediated inflammation that directly attacks joint structures, leading to erosion of cartilage and bone. This condition is relatively uncommon in dogs compared to osteoarthritis but can cause severe, progressive joint damage and significant pain when it does occur. Rheumatoid arthritis typically affects multiple joints simultaneously, with a particular predilection for the smaller joints of the feet and lower limbs, distinguishing it from many other forms of canine arthritis.

The underlying mechanism of rheumatoid arthritis involves dysregulation of the immune system, causing it to produce antibodies and inflammatory cells that attack the synovium, the tissue lining the inside of joint capsules. This autoimmune attack triggers chronic inflammation within affected joints, leading to thickening of the synovium (synovial hyperplasia), production of destructive enzymes, and progressive erosion of cartilage and underlying bone. The inflammatory process also damages ligaments and tendons around affected joints, contributing to instability and deformity. Rheumatoid factor, an autoantibody directed against the body's own immunoglobulins, is present in many but not all affected dogs and serves as an important diagnostic marker when detected.

The impact of rheumatoid arthritis on affected dogs can be substantial due to the aggressive nature of the inflammatory process and its tendency to affect multiple joints. Dogs with this condition often experience significant pain, swelling, and stiffness that impair mobility and quality of life. The bilateral and symmetric pattern of joint involvement, meaning the same joints are affected on both sides of the body, distinguishes rheumatoid arthritis from many other arthritis types and creates particular challenges for affected dogs trying to compensate for painful joints. Without treatment, the progressive erosion of joint surfaces leads to permanent deformity and loss of function. Systemic effects including malaise, fever, and weight loss may accompany the joint symptoms.

Treatment of rheumatoid arthritis differs fundamentally from treatment of degenerative arthritis because addressing the underlying immune dysregulation is essential for controlling disease progression. Immunosuppressive medications form the cornerstone of treatment, aiming to reduce the inappropriate immune attack on joint tissues. Anti-inflammatory medications help control pain and swelling while immunosuppressive therapy takes effect. With appropriate treatment initiated before extensive joint damage occurs, many dogs with rheumatoid arthritis can achieve good disease control and maintain reasonable quality of life. Early diagnosis and aggressive treatment are critical because joint damage that has already occurred cannot be reversed. Working with a veterinarian experienced in immune-mediated diseases ensures that affected dogs receive appropriate diagnostic evaluation and treatment.

The exact causes of rheumatoid arthritis in dogs remain incompletely understood, but the condition is fundamentally an autoimmune disorder in which the immune system mistakenly identifies components of the body's own joint tissues as foreign threats and mounts an inflammatory attack against them. This immune dysregulation appears to result from a combination of genetic predisposition and environmental triggers that together initiate the autoimmune process. Once started, the inflammatory cascade becomes self-perpetuating as damage to joint tissues releases additional antigens that further stimulate the immune response, creating a cycle of ongoing inflammation and destruction.

Genetic factors play an important role in susceptibility to rheumatoid arthritis, as evidenced by the increased prevalence in certain breeds and the tendency for the condition to cluster in some family lines. The specific genes involved have not been fully characterized in dogs, but research in humans has identified associations with major histocompatibility complex (MHC) genes that regulate immune recognition and response. Similar genetic factors likely contribute to canine rheumatoid arthritis susceptibility. Dogs with affected relatives may carry genetic variations that predispose their immune systems to lose tolerance for self-tissues under certain conditions. However, genetics alone do not cause the disease, as many genetically susceptible dogs never develop rheumatoid arthritis.

Environmental triggers are thought to initiate the autoimmune process in genetically susceptible individuals, though identifying specific triggers in individual cases is often impossible. Infectious agents, particularly bacteria and viruses, may trigger rheumatoid arthritis through molecular mimicry, where immune responses directed against microbial antigens cross-react with similar structures in joint tissues. Previous joint injury or inflammation from any cause may expose joint antigens to the immune system in ways that trigger autoimmune responses. Hormonal factors may influence disease development, as evidenced by differences in prevalence between male and female dogs in some studies. Stress and other factors affecting immune function may contribute to disease onset in predisposed individuals.

The immunological mechanism of rheumatoid arthritis involves both humoral (antibody-mediated) and cellular components of the immune system attacking joint tissues. B lymphocytes produce rheumatoid factor and other autoantibodies that target joint components and form immune complexes within the synovium. T lymphocytes infiltrate the synovium and coordinate the inflammatory response while directly attacking joint tissues. Macrophages and other inflammatory cells produce cytokines and destructive enzymes that break down cartilage and bone. The inflamed synovium (pannus) grows abnormally and invades adjacent cartilage and bone, directly contributing to erosive damage. This complex interplay of immune components explains why effective treatment often requires multiple approaches to modulate different aspects of the immune response.

The progressive nature of joint damage in rheumatoid arthritis results from ongoing inflammation that continuously breaks down cartilage and erodes bone. Unlike osteoarthritis, where damage accumulates gradually from mechanical wear, rheumatoid arthritis involves active destruction by inflammatory cells and enzymes. The erosive bone changes characteristic of rheumatoid arthritis occur at joint margins where the pannus tissue invades, creating the radiographic appearance that helps distinguish this condition from other forms of arthritis. Damage to supporting ligaments and the joint capsule contributes to instability and the development of joint deformities. Once joint structures are destroyed, they do not regenerate, making early intervention to halt the inflammatory process critical for preserving joint function.

The early warning signs of rheumatoid arthritis in dogs may be subtle and nonspecific, potentially delaying recognition of this serious condition. Initial symptoms often include generalized stiffness, particularly after rest, that seems out of proportion to the dog's age and activity level. Dogs may appear to have difficulty getting up or may be reluctant to engage in normal activities. Low-grade fever and general malaise may occur, with dogs seeming less energetic or interested in their surroundings than usual. Mild swelling in the feet or lower limbs may be noticed but attributed to minor injury. The insidious onset and nonspecific early symptoms mean that rheumatoid arthritis may not be suspected until more characteristic signs develop.

As the disease progresses, more specific symptoms emerge that point toward inflammatory joint disease. Multiple joints become swollen, warm, and painful, often in a symmetric pattern affecting the same joints on both sides of the body. The smaller joints of the feet (carpus, tarsus, phalanges) are typically affected earlier and more severely than larger joints, though any synovial joint can be involved. Affected joints show soft tissue swelling from synovial thickening and joint effusion rather than the bony enlargement characteristic of osteoarthritis. Dogs may shift weight frequently, seeking to relieve pressure on painful joints. Lameness may shift from limb to limb as different joints flare at different times.

Behavioral changes reflect the systemic nature of rheumatoid arthritis and the chronic pain experienced by affected dogs. Appetite often decreases, and weight loss may occur due to the metabolic effects of chronic inflammation combined with reduced food intake. Dogs may become withdrawn or irritable, particularly when painful areas are touched. Sleep may be disrupted by joint discomfort, and dogs may have difficulty finding comfortable resting positions. Activity levels decrease as movement becomes painful, and dogs may resist walking or playing. Some dogs vocalize or react defensively when their feet or limbs are handled. Depression is common in dogs with chronic painful conditions.

Physical examination findings in dogs with rheumatoid arthritis reveal characteristic patterns of joint involvement that help distinguish this condition from other arthritis types. Multiple joints show soft tissue swelling, warmth, and pain on manipulation, typically in a bilateral symmetric distribution. Range of motion is reduced in affected joints due to pain and synovial thickening. Joint instability may be present where supporting structures have been damaged by chronic inflammation. In advanced cases, joint deformities develop as erosion destroys normal joint architecture. Muscle wasting occurs in limbs with severely affected joints. Fever is often present, distinguishing rheumatoid arthritis from noninflammatory conditions. Lymph nodes may be enlarged as part of the systemic immune response.

The progression of symptoms in rheumatoid arthritis tends to follow a pattern of relapsing and remitting inflammation superimposed on steadily advancing joint damage. During flares, pain, swelling, and systemic symptoms intensify, sometimes dramatically. Between flares, symptoms may partially improve but rarely resolve completely without treatment. Over time, each flare tends to leave joints somewhat worse than before, with cumulative erosive damage and loss of function. Dogs may develop permanent lameness and deformity as joints become structurally damaged beyond the body's capacity for repair. The rate of progression varies among individuals, with some experiencing rapid destructive disease while others progress more slowly.

Certain symptoms require urgent veterinary attention because they may indicate severe disease flares, complications, or conditions that mimic rheumatoid arthritis. Sudden severe worsening of joint symptoms with high fever raises concern for septic arthritis, which requires urgent treatment. Extreme lethargy, collapse, or other signs of systemic illness warrant immediate evaluation. Dogs that suddenly become unable to walk or bear weight need prompt assessment. Any neurological symptoms such as weakness, knuckling, or coordination problems suggest potential spinal involvement or other serious conditions. Signs of adverse effects from immunosuppressive medications, including vomiting, diarrhea, increased thirst and urination, or unusual bleeding, require veterinary consultation.

Diagnosis of rheumatoid arthritis requires systematic evaluation to confirm immune-mediated joint disease while ruling out other conditions that can produce similar clinical signs. The diagnostic workup typically begins with a thorough history and physical examination, followed by laboratory testing and imaging studies. Because rheumatoid arthritis shares features with other forms of polyarthritis and inflammatory joint disease, multiple diagnostic criteria must be met before a diagnosis is established. The American College of Veterinary Internal Medicine has proposed diagnostic criteria adapted from human medicine that help standardize diagnosis of canine rheumatoid arthritis.

Laboratory testing provides important information for diagnosing rheumatoid arthritis and ruling out alternative diagnoses. A complete blood count may reveal anemia of chronic disease and elevated white blood cell counts. Chemistry panels help assess overall health and identify organ involvement or complications. Rheumatoid factor testing detects the characteristic autoantibody present in many but not all affected dogs; a positive result supports the diagnosis while a negative result does not exclude it. Joint fluid analysis (arthrocentesis) reveals inflammatory changes with increased white blood cells, predominantly neutrophils, and elevated protein levels. Culture of joint fluid helps exclude septic arthritis, which can mimic immune-mediated arthritis. Testing for infectious agents including tick-borne diseases helps rule out infection-associated polyarthritis.

Radiographic imaging provides crucial information about joint involvement and the nature of arthritic changes. Early in the disease, radiographs may show only soft tissue swelling and joint effusion. As the disease progresses, characteristic erosive changes appear, distinguishing rheumatoid arthritis from non-erosive forms of immune-mediated arthritis. Bone erosions occur at joint margins where inflammatory pannus tissue invades, creating a moth-eaten appearance. Joint space narrowing occurs as cartilage is destroyed. Subluxation (partial dislocation) and deformity develop in severely affected joints. The symmetric involvement of multiple joints, particularly the smaller distal joints, helps distinguish rheumatoid arthritis from osteoarthritis, which typically shows asymmetric involvement of larger joints.

Differential diagnosis for rheumatoid arthritis includes numerous other conditions that can cause polyarthritis in dogs. Systemic lupus erythematosus produces immune-mediated arthritis along with other organ involvement. Idiopathic immune-mediated polyarthritis is more common than rheumatoid arthritis but typically does not produce erosive changes. Infectious polyarthritis from bacteria, tick-borne organisms, or other pathogens requires identification and specific antimicrobial treatment. Drug-induced arthritis may occur as a reaction to certain medications. Neoplastic conditions including multiple myeloma and metastatic cancer can produce joint symptoms. Accurate diagnosis is essential because treatment approaches differ significantly among these conditions, and inappropriate treatment can be harmful.

Emergency treatment for rheumatoid arthritis may be necessary during severe flares that cause extreme pain and systemic illness. Dogs presenting with high fever, severe joint swelling, and inability to walk require aggressive supportive care while diagnostic evaluation proceeds. Intravenous fluids support hydration and circulation. Pain management with appropriate medications addresses acute suffering while specific treatment is initiated. Ruling out septic arthritis through joint fluid analysis and culture is critical because treatment approaches differ dramatically. Once immune-mediated disease is confirmed, high-dose immunosuppressive therapy can be initiated to quickly control severe inflammation. Hospitalization may be necessary until the dog is stable enough for outpatient management.

Immunosuppressive therapy forms the cornerstone of rheumatoid arthritis treatment because controlling the inappropriate immune response is essential for halting disease progression. Corticosteroids such as prednisone or prednisolone are typically the first-line immunosuppressive agents, providing rapid anti-inflammatory and immunosuppressive effects. Initial high doses are gradually tapered to the lowest effective maintenance dose as disease control is achieved. Additional immunosuppressive agents are often added to allow further steroid dose reduction and provide more complete immune modulation. Commonly used agents include azathioprine, cyclosporine, leflunomide, and mycophenolate, each with its own mechanism of action, efficacy profile, and potential side effects. The specific combination and dosing regimen is individualized based on disease severity, response to treatment, and tolerance of medications.

Anti-inflammatory and analgesic medications complement immunosuppressive therapy by providing additional pain control. Nonsteroidal anti-inflammatory drugs (NSAIDs) may be used cautiously in dogs also receiving corticosteroids, though the combination increases gastrointestinal and renal risk and is often avoided. When NSAIDs are used, they should be selected and monitored carefully with attention to gastrointestinal protection. Additional pain medications including gabapentin for neuropathic pain and tramadol for breakthrough pain may be helpful. Adequate pain control is important for maintaining quality of life and allowing dogs to remain mobile, which helps prevent muscle wasting and joint stiffness.

Supportive care measures enhance the effectiveness of medical treatment and help maintain function and quality of life. Weight management reduces stress on affected joints and may improve mobility. Physical therapy and rehabilitation help maintain muscle strength and joint range of motion despite ongoing disease. Gentle, low-impact exercise such as swimming or controlled leash walking keeps dogs mobile without excessive joint stress. Heat therapy may relieve stiffness and discomfort. Orthopedic bedding provides comfortable rest for painful joints. Environmental modifications including non-slip flooring and ramps reduce the demands placed on compromised joints during daily activities.

Disease-modifying approaches beyond traditional immunosuppressive therapy are being investigated for canine rheumatoid arthritis. Biologic therapies targeting specific cytokines involved in the inflammatory cascade have revolutionized treatment of human rheumatoid arthritis and hold promise for veterinary applications. Stem cell therapy and other regenerative medicine approaches are being studied for potential benefits in immune-mediated joint disease. Dietary modifications including omega-3 fatty acid supplementation may provide modest anti-inflammatory benefits. As understanding of canine rheumatoid arthritis advances, additional treatment options will likely become available.

Treatment planning requires individualization based on disease severity, response to therapy, and patient-specific factors. Dogs with early mild disease may achieve control with relatively conservative immunosuppressive regimens. Those with severe or rapidly progressive disease require more aggressive multi-drug approaches. Regular monitoring through physical examination, blood work, and periodic imaging assesses response to treatment and detects complications. Treatment adjustments are made based on disease activity, with the goal of maintaining remission using the lowest effective medication doses. Most dogs require long-term, often lifelong, treatment, though some may eventually be tapered off medications while remaining in remission.

The concept of recovery in rheumatoid arthritis differs from conditions that can be cured, as the underlying immune dysregulation typically persists and requires ongoing management. However, with appropriate treatment, many dogs achieve remission, a state where disease activity is minimal or absent and quality of life is preserved. Initial response to treatment may be seen within days to weeks as inflammation comes under control and pain decreases. Full optimization of the treatment regimen typically requires several months of adjustments based on the dog's response. Dogs that achieve remission can enjoy good quality of life for extended periods, though vigilance for flares remains necessary.

Ongoing care requirements for dogs with rheumatoid arthritis include consistent medication administration, regular monitoring, and attention to factors that may trigger disease flares. Immunosuppressive medications must be given as prescribed, as missed doses or premature discontinuation often leads to disease recurrence. Regular veterinary visits, typically every one to three months during stable periods, allow assessment of disease activity and monitoring for medication side effects. Blood work is performed periodically to monitor for bone marrow suppression, liver effects, and other complications of immunosuppressive therapy. Joint examinations track disease activity and identify emerging problems. Any signs of flaring require prompt veterinary evaluation for treatment adjustment.

Prognostic factors in rheumatoid arthritis influence the likelihood of achieving and maintaining disease control. Early diagnosis and treatment initiation before extensive joint damage occurs is associated with better outcomes, as destroyed joint structures cannot be regenerated. The severity of erosive changes at diagnosis affects long-term function even if disease activity is controlled. Response to initial treatment predicts long-term prognosis, with dogs that achieve rapid remission tending to do better than those requiring multiple medication adjustments. Owner compliance with treatment protocols directly impacts outcomes, as consistent medication administration and monitoring are essential. The presence of complications or concurrent conditions may affect treatment options and overall prognosis.

Long-term outlook for dogs with rheumatoid arthritis is variable but can be favorable with appropriate management. Many dogs achieve good disease control and maintain reasonable quality of life for years. Flares may occur despite ongoing treatment, requiring temporary treatment intensification. Progressive joint damage may occur over time despite treatment, leading to increasing disability in some dogs. The requirement for lifelong immunosuppressive therapy carries risks of side effects and complications that must be balanced against disease control. Quality of life should be regularly assessed, and treatment goals may shift from disease control to comfort care as the condition progresses in some patients. With committed owners and experienced veterinary care, many dogs with rheumatoid arthritis live comfortably for extended periods.

Primary prevention of rheumatoid arthritis is challenging because the exact causes of immune dysregulation are incompletely understood and likely involve complex interactions between genetic and environmental factors. No specific measures have been proven to prevent rheumatoid arthritis in dogs at genetic risk. General immune health support through proper nutrition, appropriate vaccination, parasite control, and minimizing unnecessary stress may theoretically help maintain immune regulation, though direct evidence for preventive benefit is lacking. Avoiding known triggers for immune dysregulation, where identifiable, may reduce risk in susceptible individuals.

Breeding considerations for preventing rheumatoid arthritis are complicated by the complex genetics of autoimmune diseases. Dogs with confirmed rheumatoid arthritis should not be bred, as they likely carry genetic risk factors that could be transmitted to offspring. First-degree relatives of affected dogs may carry similar risk factors and should be bred only with careful consideration. The relatively low prevalence of rheumatoid arthritis in dogs makes population-wide screening impractical. Breeders aware of rheumatoid arthritis in their lines should work with veterinary geneticists to make informed breeding decisions. As genetic factors in canine autoimmune diseases become better characterized, genetic testing may eventually enable identification of at-risk individuals before breeding.

Nutritional factors may influence immune function and potentially affect rheumatoid arthritis risk, though specific preventive dietary strategies have not been established for dogs. Balanced nutrition that meets all requirements supports normal immune function. Omega-3 fatty acids have anti-inflammatory properties that may be beneficial for general immune health. Avoiding excessive supplementation with immune-stimulating substances is prudent in dogs from breeds or lines with autoimmune disease history. Maintaining appropriate body condition prevents obesity-related immune dysregulation. Consultation with a veterinary nutritionist can help optimize diet for dogs considered at increased autoimmune disease risk.

Regular veterinary care enables early detection if rheumatoid arthritis does develop, allowing treatment before extensive joint damage occurs. Dogs from breeds with increased autoimmune disease risk may benefit from more frequent wellness examinations with particular attention to joint health. Any signs of joint stiffness, swelling, or lameness should prompt veterinary evaluation rather than being attributed to minor injury or aging. Early diagnosis allows treatment initiation during the window when joint preservation is still possible. Dogs with other autoimmune conditions should be monitored for polyarthritis development, as multiple autoimmune diseases can occur in the same individual.

Early intervention when immune-mediated joint disease is suspected can significantly improve outcomes by controlling inflammation before extensive erosive damage occurs. Dogs presenting with symmetric polyarthritis should receive expedited diagnostic workup to confirm or exclude rheumatoid arthritis. Treatment should be initiated promptly once diagnosis is established, as joint damage that occurs before treatment is instituted cannot be reversed. Aggressive initial therapy to achieve rapid remission followed by careful dose reduction to maintenance levels optimizes the balance between disease control and treatment side effects. Close monitoring during the early treatment period allows rapid adjustment if initial response is inadequate.

Daily management of dogs living with rheumatoid arthritis requires consistent attention to medication administration, pain assessment, and factors affecting disease activity. Immunosuppressive medications must be given reliably at prescribed times, as irregular dosing can lead to disease flares. Pain levels should be assessed daily using observation of mobility, activity level, and behavior. A log or journal of observations helps identify patterns and provides useful information for veterinary consultations. Dogs should be monitored for signs of medication side effects including increased thirst and urination (steroids), gastrointestinal upset, or unusual bleeding or bruising. Any concerning changes warrant prompt communication with the veterinary team.

Home environment modifications help dogs with rheumatoid arthritis maintain mobility and comfort despite joint limitations. Non-slip flooring or area rugs with non-skid backing prevent slipping that can stress damaged joints. Ramps provide access to furniture and vehicles without jumping. Orthopedic beds with adequate cushioning support painful joints during rest and make rising easier. Raised food and water bowls reduce the need to bend painful joints during eating and drinking. Temperature control is important, as many dogs with inflammatory arthritis experience increased stiffness in cold or damp conditions. Creating comfortable rest areas away from drafts and providing warm bedding can help.

Maintaining quality of life for dogs with rheumatoid arthritis involves balancing disease management with opportunities for enjoyment and engagement. Activity should be encouraged within the limits imposed by joint damage and current disease activity. Short, gentle walks maintain mobility and provide mental stimulation without excessive joint stress. Swimming offers excellent low-impact exercise for dogs with access to appropriate facilities. Mental enrichment through food puzzles, scent games, and training exercises provides stimulation without physical stress. Social interaction with family members remains important for emotional wellbeing. Finding activities the dog can still enjoy helps prevent the depression that often accompanies chronic painful conditions.

Ongoing monitoring enables early detection of disease flares and treatment complications. Owners should watch for increased joint swelling, heat, or pain that may indicate flaring disease activity. Fever, lethargy, or decreased appetite warrant veterinary consultation. Signs of potential medication side effects should be reported promptly. Regular veterinary examinations allow professional assessment of disease status and joint damage progression. Blood work monitoring detects hematologic or organ complications of immunosuppressive therapy. Periodic radiographs may be recommended to track erosive changes. Open communication between owners and the veterinary team ensures timely treatment adjustments when needed.

Caregiving for dogs with chronic immune-mediated disease presents ongoing challenges that deserve acknowledgment and support. The emotional impact of watching a beloved pet cope with a progressive, incurable condition can be significant. Financial demands of ongoing treatment, monitoring, and management create stress for many families. Connecting with support resources including online communities of owners managing similar conditions provides practical tips and emotional validation. Quality of life assessment tools help guide decisions about treatment intensity and ensure the dog's wellbeing remains central to management decisions. End-of-life planning should be discussed openly with the veterinary team when the time is appropriate, ensuring that decisions reflect the dog's best interests.

Certain breeds appear to be predisposed to rheumatoid arthritis, though the condition can occur in any breed or mixed breed dog. Small to medium breeds including Shetland Sheepdogs, Toy and Miniature Poodles, and various terrier breeds are reported to have elevated risk in some studies. The condition appears to occur more commonly in smaller dogs than in giant breeds, distinguishing its breed distribution from osteoarthritis. Female dogs may be affected more frequently than males in some breed populations, suggesting hormonal influences on disease expression. The relatively low overall prevalence of rheumatoid arthritis makes breed-specific prevalence data limited and sometimes inconsistent across studies.

Breeds with increased susceptibility to other autoimmune diseases may also carry elevated rheumatoid arthritis risk due to shared genetic factors affecting immune regulation. Breeds predisposed to systemic lupus erythematosus, immune-mediated hemolytic anemia, or other autoimmune conditions may have generalized tendencies toward immune dysregulation that increase susceptibility to multiple autoimmune manifestations. German Shepherds, Doberman Pinschers, and several other breeds known for autoimmune disease predisposition should be monitored for polyarthritis symptoms. Individual dogs with personal or family history of autoimmune conditions face elevated risk and deserve particular vigilance for arthritis development.

Screening recommendations for breeds at risk of rheumatoid arthritis are not well established due to the relatively low prevalence and lack of reliable presymptomatic markers. Dogs from affected lines should receive regular veterinary examinations with attention to joint health. Any signs of joint swelling, stiffness, or lameness in predisposed breeds warrant thorough diagnostic evaluation including consideration of immune-mediated causes. Breeders aware of rheumatoid arthritis in their lines should maintain careful records and consider removing affected individuals and their close relatives from breeding programs. As understanding of genetic factors in canine autoimmune diseases advances, more specific screening and prevention strategies may become available.

Rheumatoid arthritis shares features with and must be distinguished from other forms of immune-mediated polyarthritis in dogs. Systemic lupus erythematosus (SLE) can produce erosive or non-erosive polyarthritis along with involvement of other organ systems including kidneys, skin, and blood cells. Idiopathic immune-mediated polyarthritis (IMPA) is more common than rheumatoid arthritis and typically does not produce erosive joint changes. Drug-induced polyarthritis may occur as a reaction to certain medications and resolves when the offending drug is discontinued. Reactive polyarthritis can follow infections elsewhere in the body. Distinguishing among these conditions requires comprehensive diagnostic evaluation because treatment approaches and prognoses differ.

Several conditions produce clinical signs that may be confused with rheumatoid arthritis during initial evaluation. Infectious polyarthritis caused by bacteria, tick-borne organisms such as Lyme disease, or fungal agents requires identification of the causative organism and specific antimicrobial treatment rather than immunosuppression. Osteoarthritis affects larger joints in an asymmetric pattern and shows degenerative rather than erosive radiographic changes. Neoplastic conditions including multiple myeloma and synovial cell sarcoma can produce joint symptoms. Degenerative joint disease secondary to developmental orthopedic conditions may affect multiple joints. Thorough diagnostic evaluation ensures accurate diagnosis and appropriate treatment selection.

Complications of rheumatoid arthritis and its treatment include secondary conditions that may develop during the course of the disease. Progressive joint destruction leads to permanent deformity and disability in dogs with poorly controlled disease. Secondary osteoarthritis develops in joints damaged by inflammatory erosion. Immunosuppressive therapy increases susceptibility to infections, including opportunistic organisms that rarely cause disease in immunocompetent animals. Long-term corticosteroid use can cause hyperadrenocorticism (Cushing's syndrome), diabetes mellitus, and other metabolic complications. Amyloidosis, a condition where abnormal protein deposits in organs, may develop secondary to chronic inflammation. Recognition of these potential complications guides comprehensive monitoring and management of dogs with rheumatoid arthritis.